Case studies showing clinical signs and management of cutaneous  toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients  with solid tumours.
Desar
Ingrid M E
IM
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. i.desar@AIG.umcn.nl
Bovenschen
H Jorn
HJ
Timmer-Bonte
Anja J N H
AJ
Cantarini
Mireille V
MV
Van Der Graaf
Winette T A
WT
Van Rossum
Michelle M
MM
Van Herpen
Carla M L
CM
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000009:adverse effects; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors; D048730:MAP Kinase Kinase Kinase 2 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced*
C517975:AZD 6244; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D048730:MAP Kinase Kinase Kinase 2; D048369:MAP Kinase Kinase 1